Shares of Shield Therapeutics PLC (LON:STX) reached a new 52-week low during trading on Monday . The stock traded as low as GBX 33 ($0.46) and last traded at GBX 33.50 ($0.46), with a volume of 2000 shares trading hands. The stock had previously closed at GBX 34.50 ($0.48).
STX has been the subject of several research analyst reports. Peel Hunt restated a “buy” rating and issued a GBX 220 ($3.04) price target on shares of Shield Therapeutics in a research report on Tuesday, October 31st. FinnCap restated a “buy” rating and issued a GBX 265 ($3.66) price target on shares of Shield Therapeutics in a research report on Tuesday, November 21st. Finally, Liberum Capital restated an “under review” rating on shares of Shield Therapeutics in a research report on Monday, February 5th.
The stock has a market cap of $12.22 and a PE ratio of -223.33.
COPYRIGHT VIOLATION WARNING: “Shield Therapeutics (STX) Hits New 52-Week Low at $33.00” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/02/12/shield-therapeutics-stx-hits-new-52-week-low-at-33-00.html.
Shield Therapeutics Company Profile
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.